ARCHIVES

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

DCT Board Oks Recompetition Of Master Agreement For BRM Trials

February 4, 1983

NIH Lifts Patient Limit On Gene Modified TIL Study; 6 Treated So Far

April 13, 1990

Bishop Completes Term As NCAB Chairman; Terms Of Five Extended Awaiting W.H. Action.

February 25, 2000

Also in this 8-page issue: John Mendelsohn selected for BMS award. National Coalition for Cancer Survivorship and The Wellness Community begin advocacy initiative.

March 19, 2004

FDA News: FDA Eases Two-Trial Standard For Proof Of Drug Efficacy

March 21, 1997

House committee Seeks $239 Million Cut In Clinton’s NIH Budget

March 11, 1994